Mitsubishi Tanabe Pharma (MTPA) Collaborates with Massachusetts General Hospital (MGH) for ALS Biomarker Study

Mitsubishi Tanabe Pharma (MTPA) Collaborates with Massachusetts General Hospital (MGH) for ALS Biomarker Study

Shots:

  • Mitsubishi Tanabe Pharma (MTPA) enters into a collaboration with Massachusetts General Hospital (MGH) Neurological Clinical Research Institute (NCRI) to conduct ALS biomarker study for identification of biomarkers in patients with amyotrophic lateral sclerosis (ALS)
  • The ALS biomarker study will evaluate 4 biomarkers enrolling 200 patients receiving Radicava (edaravone) for 24wks. across 40 sites and will be conducted & sponsored by MGH & MTPA respectively with its expected interim analyses in H2’19
  • RADICAVA (edaravone, IV) is a neuroprotective agent indicated for the treatment of ALS and has received approval in the US, Japan and South Korea in May’17, Jun’15 & Dec’15 respectively for ALS

Click here to read full press release/ article | Ref: Mitsubishi Tanabe Pharma | Image: MGH